US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Lundbeck presents new Phase II asedebart data in Cushing’s disease at ENDO 2026

· Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing’s disease (CD) · Urinary free cortisol (UFC) normalization is a clinically relevant measure in CD, where chronic cortisol excess is a key driver of morbidity, mortality and quality-of-life burden · Preliminary Phase II Part A data showed UFC normalization in most evaluable adults with CD who completed individualized intravenous dose titration with asedebart[1] Valby, Denmark, Sunday 14 June 2026 – H. Lundbeck A/S

Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026

· Upcoming presentations at ENDO 2026 highlight Lundbeck’s Focused Innovator strategy and continued expansion into rare neuroendocrine diseases with high unmet medical needs · The scientific program showcases Lundbeck’s investigational neurohormonal and neuroimmunological targeted therapeutic candidates, asedebart and Lu AG22515, respectively   · Preliminary Phase II data for asedebart, an investigational anti-adrenocorticotropic hormone (ACTH) monoclonal antibody in Cushing’s disease (CD), demonstrate Lundbeck’s biomarker-supported approach to evaluating novel therapeutic mechanisms

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

· The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly migraine days versus placebo over Weeks 1–12 in patients with one to four prior preventive treatment failures · Bocunebart was generally well tolerated, with no new safety signals identified · The totality of the presented clinical data from the bocunebart Phase I-IIb program strengthens the evidence for PACAP pathway inhibition as a novel therapeutic approach for people severely impacted by migraine

Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments

Collaboration’s initial focus will focus on two antibody programs targeting CNS diseasesVALBY, Denmark & AMSTERDAM, 03 June 2026 – H. Lundbeck A/S (Lundbeck), a global biopharmaceutical company focused exclusively on brain health, and Cradle, a leading AI platform for protein engineering, today announced a partnership to help Lundbeck discover and optimize biotherapeutics that ultimately can improve patient outcomes. It is estimated that more than half of the world’s population is impacted by brain disorders, and the effects are felt throughout society. Speeding up innovation time to

Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine

· Approval granted by South Korea’s Ministry of Food and Drug Safety (MFDS) · Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the preventive treatment of migraine in adults · Authorization supported by the Phase 3 SUNRISE trial conducted in a predominantly Asian population with chronic migraine · Provides a new preventive treatment option for people living with migraine in Korea Valby, Denmark, 26 May 2026 – H. Lundbeck A/S (Lundbeck) today announced that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted marketing

Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing’s disease

· Congenital adrenal hyperplasia (CAH) and Cushing’s disease (CD) are rare disorders characterized by excess adrenocorticotropic hormone (ACTH) produced in the brain[1,2] · Current treatments are limited by suboptimal disease control and treatment-related complications[3,4] · Asedebart (Lu AG13909) is a novel, investigational anti-ACTH monoclonal antibody targeting underlying disease pathology · Proof-of-concept trials are currently ongoing to evaluate efficacy and safety of asedebart in CD and CAH Valby, Denmark, 18 May 2026 – Lundbeck today announced that orphan drug

Strong start to 2026: +21% CER revenue growth (+13% CER underlying)

Key highlights Lundbeck’s total revenue grew by +21% CER[1] (+14% DKK) to DKK 7,125 million in the first quarter of 2026, with all regions contributing double-digit growth. As planned, Lundbeck made progress sharpening its commercial model by establishing 27 partner markets[2]. Adjusting for the planned one-time DKK 470 million inventory build in these markets, total revenue grew by +13% CER · United States: DKK 3,482 million (+20% CER; +6% DKK) · Europe: DKK 1,799 million (+24% CER; +25% DKK) · International Operations: DKK 1,616 million (+13% CER; +6% DKK) · Adjusting

Lundbeck raises financial guidance for 2026

H. Lundbeck A/S (Lundbeck) raises financial guidance for the full-year revenue and adjusted EBITDA growth at constant exchange rates (CER). Lundbeck has increased its 2026 revenue outlook, primarily reflecting stronger expected full-year volumes for Vyepti[ ][®] in the U.S., anticipated delay of Abilify Maintena[®] generic entry in key markets outside US, and a stronger-than-expected start in the newly established partner markets. Lundbeck now expects R&D investments of approximately DKK 5.6 - 5.9 billion. The updated guidance at CER is outlined below: Financial guidance for 2026

Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)

· The one-year INFUSE study observed patient-reported migraine-related cognitive symptoms at baseline and changes over 6 months in those with at least one prior anti-calcitonin gene-related peptide (anti-CGRP) treatment failure Valby, Denmark, 19 April 2026 – H. Lundbeck A/S (Lundbeck) today presented  new real-world 6-month results from the INFUSE study at the American Academy of Neurology (AAN) 2026 Annual Meeting, underscoring the importance of evaluating the broad burden of migraine beyond headache and migraine frequency.

Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

· Seven abstracts represent data across migraine, childhood-onset epilepsy and multiple system atrophy (MSA), highlighting Lundbeck’s biology-driven approach to developing treatments for serious brain diseases · Oral presentation of new Phase 1 safety and tolerability data for bocunebart (Lu AG09222), an investigational anti-PACAP monoclonal antibody in migraine prevention · Three VYEPTI® (eptinezumab) abstracts include clinical data and new real-world evidence in migraine · Neuro-rare pipeline updates feature long-term data for bexicaserin in developmental and epileptic

Lundbeck held its Annual General Meeting on 18 March 2026 at the company’s registered office

H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted and the annual report was approved at the annual general meeting. The proposal to distribute a dividend of 36% of the net profit and 30% of net profit adjusted for the impairment loss of the planned divestment of a non-core production site in Italy for the accounting year 2025, corresponding to DKK 1.15 per share, or a total dividend of DKK 1,145 million, was adopted. The Remuneration Report for 2025 was approved in the advisory vote. Dorothea Wenzel, Lene Skole-Sørensen, Lars Erik

Lundbeck advances Parkinson’s research with new Phase 1b data at AD/PD™ 2026

· Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease, to be presented at the 2026 AD/PD™ Conference · Data evaluated safety, tolerability, pharmacokinetics and early clinical signals of Lu AF28996 · Five accepted presentations reflect Lundbeck’s growing pipeline within movement disorders, with Parkinson’s disease and multiple system atrophy (MSA) clinical development programs Valby, Denmark, 16 March 2026 – H. Lundbeck A/S (Lundbeck) today announced that new data from a Phase 1b proof-of-mechanism trial of Lu AF28996, a novel

Lundbeck appoints Chief AI Officer

Valby, Denmark, 10 March 2026 – H. Lundbeck A/S (Lundbeck) today announced the appointment of Markus Kede as Senior Vice President, Chief AI Officer. He will join the Executive Leadership Team and report to President and CEO, Charl van Zyl. The appointment marks an important step in Lundbeck’s ambition to become a bionic company. As a key pillar of Lundbeck’s Focused Innovator strategy, AI plays a critical role in transforming how the company operates, innovates, and scales its impact for patients. “As we advance our Focused Innovator strategy, becoming a bionic company is one of our

Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial

· MASCOT is a first-of-its-kind, Phase 3 trial supporting the development of amlenetug, an investigational therapy for people living with multiple system atrophy (MSA), a rare and fatal neurodegenerative disorder[1] · Amlenetug is a novel monoclonal antibody that demonstrated promising results in a Phase 2 trial, suggesting potential to slow disease progression in MSA · Early completion of randomization underscores the significant unmet need in MSA, strong collaboration with patient and investigator communities, and Lundbeck’s robust research and development capabilities · Headline

To the shareholders of H. Lundbeck A/S

NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: WEDNESDAY, 18 MARCH 2026 AT 10:00 AM CET The annual general meeting will be held at the offices of the Company at: H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby Agenda In accordance with Article 8.1 of the Articles of Association, the agenda of the meeting is as follows: 1. Report of the Board of Directors on the Company’s activities during the past year. 2. Presentation and adoption of the annual report. 3. Resolution on the appropriation of

Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention

· The intravenous (IV) part of the phase IIb dose-finding PROCEED trial of bocunebart (Lu AG09222) met its primary endpoint in migraine prevention, demonstrating a statistically significant difference to placebo in the change from baseline in the number of monthly migraine days (MMDs) over weeks 1 to 12 in a population that experienced past treatment failures. · The results demonstrate the potential of bocunebart in severe migraine. · Additional analyses will be done to better understand the dose–response relationship across the investigated doses. · Based on this positive outcome,

Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck. +--+-----------------+------------+---------+|1.|Details of the || |person || |discharging || |managerial || |responsibilities || |/ person closely || |associated |+--+-----------------+------------+--------

Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck. +--+-----------------+----------+---------+|1.|Details of the || |person || |discharging || |managerial || |responsibilities || |/ person closely || |associated |+--+-----------------+----------+---------+|a)|Name

Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026

Key highlights Lundbeck’s total revenue grew by +13% CER[1] (+12% DKK) to DKK 24,630 million in 2025, driven primarily by strong performance in the U.S. and Europe. · United States: DKK 13,287 million (+21% CER; +17% DKK) · Europe: DKK 5,819 million (+13% CER; +13% DKK) · International Operations: DKK 4,858 million (-3% CER; -7% DKK) The revenue of Lundbeck’s strategic brands increased by +19% CER (+15% DKK), reaching DKK 19,011 million, representing 77% of total revenue. · Rexulti[®]: DKK 6,205 million (+23% CER; +19% DKK) · Brintellix[®]/Trintellix[®]: DKK 4,554

Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference

· New six-month results from the Vyepti® (eptinezumab) 12-month, real-world INFUSE study presented at the 2026 Headache Cooperative of the Pacific (HCOP) Annual Conference, Ojai, California[1] · The INFUSE study includes adults with migraine who had failed at least one preventive anti-calcitonin gene–related peptide (aCGRP) treatment[1] · Clinically meaningful improvements reported across migraine frequency, responder rates and other patient-reported outcomes in adults switching to eptinezumab[1] Valby, Denmark, 30 January 2026 – H. Lundbeck A/S (Lundbeck) today announced six-month

Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck. +--+-----------------+----------+---------+|1.|Details of the || |person || |discharging || |managerial || |responsibilities || |/ person closely || |associated |+--+-----------------+----------+---------+|a)|Name

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media